NDATOPICALSOLUTION
Approved
Nov 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
ROGAINE EXTRA STRENGTH (FOR MEN) (minoxidil) by Design Pharmaceuticals is clinical pharmacology 1. First approved in 1997.
Drug data last refreshed 11h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Rogaine Extra Strength is a topical minoxidil 5% solution indicated for androgenetic alopecia (male pattern baldness) in men. It functions as a peripheral vasodilator that enhances microcirculatory blood flow to hair follicles, stimulating hair growth and slowing hair loss. The exact mechanism of action in promoting hair growth remains incompletely understood, though improved follicle perfusion is the leading hypothesis.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and transition planning for generic environment.
Mechanism of Action
CLINICAL PHARMACOLOGY 1. General Pharmacologic Properties Minoxidil is an orally effective direct acting peripheral vasodilator that reduces elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. Microcirculatory blood flow in animals is enhanced or maintained…
Worked on ROGAINE EXTRA STRENGTH (FOR MEN) at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.